参考文献/References:
[1] 高鹤丽,刘亮,王文权,等.2017欧洲神经内分泌肿瘤学会共识解读:胰腺神经内分泌瘤诊治更新要点[J].中华外科杂志,2018,56(11):809-812.DOI:10.3760/cma.j.issn.0529-5815.2018.11.003.
[2] 吴文铭,陈洁,白春梅,等.中国胰腺神经内分泌肿瘤诊疗指南(2020)[J].中华外科杂志,2021,59(6):401-421.DOI:10.3760/cma.j.cn112139-20210319-00135.
[3] Fajans SS,Vinik AI.Insulin-producing islet cell tumors[J].Endocrinol metab clin North Am,1989,18(1):45-74.DOI:10.1016/S0889-8529(18)30388-8.
[4] De León DD,Stanley CA.Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia[J].Best Pract Res Clin Endocrinol Metab,2013,27(6):763-769.DOI:10.1016/j.beem.2013.06.005.
[5] Hattori N,Ishihara T,Saiki Y,et al.Insulinoma with normal plasma insulin concentrations and insulin/glucose ratios during hypoglycemic episodes[J].Intern Med,1994,33(12):813-816.DOI:10.2169/internalmedicine.33.813.
[6] Piovesan A,Pia A,Visconti G,et al.Proinsulin-secreting neuroendocrine tumor of the pancreas[J].J Endocrinol Invest,2003,26(8):758-761.DOI:10.1007/BF03347360.
[7] Czupryniak L,Strzelczyk J,Drzewoski J.Diagnostic difficulties in long-standing insulinoma with near-normal plasma insulin levels[J].J Endocrinol Invest,2005,28(2):170-174.DOI:10.1007/BF03345362.
[8] Cryer PE,Axelrod L,Grossman AB,et al. Evaluation and management of adult hypoglycemic disorders:an Endocrine Society Clinical Practice Guideline[J].J Clin Endocrinol Metab,2009,94(3):709-728.DOI:10.1210/jc.2008-1410.
[9] Nauck MA,Meier JJ.Diagnostic accuracy of an "amended" insulin-glucose ratio for the biochemical diagnosis of insulinomas[J].Ann Intern Med,2012,157(11):767-75.DOI:10.7326/0003-4819-157-11-201212040-00004.
[10] 吴文铭,姜佳霖,赵玉沛.胰岛素瘤定位及手术方式选择[J].中国实用外科杂志,2019,39(9):925-929.DOI:10.19538/j.cjps.issn1005-2208.2019.09.11.
[11] Zhu L,Xue H,Sun H,et al.Insulinoma Detection with MDCT:Is there a role for Whole-Pancreas perfusion?[J].AJR AJR Am J Roentgenol,2017,208(2):306-314.DOI:10.2214/AJR.16.16351.
[12] Mehrabi A,Fischer L,Hafezi M,et al.A systematic review of localization,surgical treatment options,and outcome of insulinoma[J].Pancreas,2014,43(5):675-686.DOI:10.1097/MPA.0000000000000110.
[13] 陈恩洪,刘敏丰,顾元龙,等.胰腺神经内分泌肿瘤的定位诊断进展[J].肝胆胰外科杂志,2020,32(3):188-192.DOI:10.11952/j.issn.1007-1954.2020.03.015.
[14] 高娟娟,王清.胰岛细胞瘤的PET/CT诊断新进展[J].中国实验诊断学,2018,22(2):351-354.DOI:10.3969/j.issn.1007-4287.2018.02.056.
[15] Reubi JC,Waser B.Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting[J].Eur J Nucl Med Mol Imaging,2003,30(5):781-793.DOI:10.1007/s00259-003-1184-3.
[16] Körner M,Stöckli M,Waser B,et al.GLP-1 receptor expression in human tumors and human normal tissues:potential for in vivo targeting[J].J Nucl Med,2007,48(5):736-743.DOI:10.2967/jnumed.106.038679.
[17] 罗亚平,潘青青,要少波,等.68Ga-exendin-4PET/CT显像定位诊断胰岛素瘤[J].中华核医学与分子影像杂志,2017,37(3):137-141.DOI:10.3760/cma.j.issn.2095-2848.2017.03.004.
[18] 罗亚平,潘青青,李方,等.68Ga-exendin-4PET-CT诊断隐匿性胰岛素瘤的前瞻性队列研究[J].中华外科杂志,2018,56(11):837-842.DOI:10.3760/cma.j.issn.0529-5815.2018.11.009.
[19] Sharma P,Arora S,Karunanithi S,et al.Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma[J].Q J Nucl Med Mol Imaging,2016,60(1):69-76.
[20] Wild D,Christ E,Caplin ME,et al.Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas[J].J Nucl Med,2011,52(7):1073-1078.DOI:10.2967/jnumed.110.085142.
[21] Karls S,Gold R,Kravets S,et al.Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms[J].Ann Nucl Med,2021,35(9):1066-1077.DOI:10.1007/s12149-021-01642-3.
[22] Panagiotidis E,Alshammari A,Michopoulou S,et al.Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Managementin Patients with Neuroendocrine Tumors[J].J Nucl Med,2017,58(1):91-96.DOI:10.2967/jnumed.116.178095.